--- title: "韩国的医疗保健热潮催生了新的亿万富翁" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/283206608.md" description: "韩国的医疗保健行业正在蓬勃发展，制药公司追求丰厚的合作伙伴关系，创造了新的亿万富翁。三春堂制药的尹大仁以 59 亿美元的净资产位列全国富豪榜第十，得益于与第一三共达成的一项减肥产品交易。新晋亿万富翁包括 ABL Bio 的李相勋（14 亿美元）和 Voronoi 的金炫泰（13 亿美元）。医疗保健财富的崛起反映了向先进研发的转变，韩国公司与全球企业签署了更多的联合研究协议，标志着行业的重大转型" datetime: "2026-04-18T01:57:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283206608.md) - [en](https://longbridge.com/en/news/283206608.md) - [zh-HK](https://longbridge.com/zh-HK/news/283206608.md) --- # 韩国的医疗保健热潮催生了新的亿万富翁 Yoon Dae-in, chairman of Sam Chun Dang Pharm, joined the ranks of the nation’s 50 richest this year at the 10th place after his company struck a deal to develop a weight-loss product. Dae-in, with a net worth of $5.9 billion, has now surpassed many tech and media tycoons in wealth following the company’s agreement with Japan’s Daiichi Sankyo signed in January to develop a pill that works similarly to the weight-loss injectable Wegovy made by Denmark-based Novo Nordisk, according to U.S. magazine _Forbes_. Two additional pharmaceutical entrepreneurs have entered the rankings for the first time. One of them is biologist Lee Sang-hoon with a net worth of $1.4 billion, ranking 39th in the country. He is the chairman and CEO of ABL Bio, which develops antibodies to improve treatment outcomes for cancer and neurodegenerative diseases. Lee Sang-hoon, chairman and CEO of ABL Bio. Photo courtesy of the company It signed a $2.6 billion technology-transfer deal with U.S.-based pharma company Eli Lilly in November last year. Another new billionaire is Hyuntae Kim (with a net worth of $1.3 billion), CEO of Voronoi, which is known for its AI-powered drug discovery platform and has two prospective cancer treatments in development. These newly created fortunes underscore the growing prominence of South Korea’s healthcare sector, and more specifically biotech, as a pathway to wealth in a country long dominated by industries such as electronics, semiconductors and online gaming. Six of the country’s 50 richest are in the healthcare industry, with one of them, Seo Jung-jin, claiming the third place with $8.1 billion in net worth. Ho-Cheol Lee, senior analyst at Shinhan Securities, building credibility with global pharmaceutical leaders has been central to the sector’s rise. Over the past year, Korean firms have signed more than a dozen joint research agreements with multinational companies, up from seven in 2024. "This marks a dramatic acceleration," he told _Forbes_. "Until 2023, the sector averaged fewer than three such deals annually." The increasing global profile of South Korea’s pharmaceutical players reflects a broader transition from domestic manufacturing to advanced research and development, according to Lee. This shift, he says, has been driven by "several pioneer companies that successfully secured multibillion dollar licensing deals with Big Pharma." Among these trailblazers are Jung-jin, co-founder of cancer-treating drugs producer Celltrion and Park Soon-jae ($2.6 billion in net worth), founder of Alteogen. The latter secured a $450 million licensing agreement with Merck in 2024 for a cancer therapy, sending its shares higher and earning Park a debut on the country’s rich list that year. "These milestones proved that Korean biotech could move beyond domestic production to high-stakes research and development," says Lee. ### 相关股票 - [4568.JP](https://longbridge.com/zh-CN/quote/4568.JP.md) - [NVO.US](https://longbridge.com/zh-CN/quote/NVO.US.md) - [LLY.US](https://longbridge.com/zh-CN/quote/LLY.US.md) - [MRK.US](https://longbridge.com/zh-CN/quote/MRK.US.md) - [SHG.US](https://longbridge.com/zh-CN/quote/SHG.US.md) - [DSNKY.US](https://longbridge.com/zh-CN/quote/DSNKY.US.md) ## 相关资讯与研究 - [新加坡康桥资本与 GHO 合并 组成全球最大医疗保健投资管理平台 | 联合早报网](https://longbridge.com/zh-CN/news/287080690.md) - [涉 93.22% 控股权，重庆渝富拟清仓科瑞制药，民企机会来了](https://longbridge.com/zh-CN/news/286905825.md) - [百济神州，制药界的 “新物种”](https://longbridge.com/zh-CN/news/286376124.md) - [纯粹的仿制药巨头，不存在了](https://longbridge.com/zh-CN/news/286855423.md) - [招银国际：AI 有望改变创新药研发范式 行业有望从概念验证迈向价值兑现](https://longbridge.com/zh-CN/news/286862777.md)